CEACAM5 and neoplasm: The development of three-dimensional models composed of intestinal organoids derived from tumor fragments combined with T lymphocytes and fibroblasts has allowed the short-term evaluation of immunotherapy approaches based on the use of bispecific antibodies (TCB), such as cibisatamab (CEA-TCB), and a new CEACAM5-TCB antibody, in combination with a fibroblast agonist FAP-4-1BBL antibody [66].